Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 17/20 | 1.00 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326464 | 1.00 | HCRTR2 (1.00) | HCRTR2HCRTR1MEN1KMT2AKDM4E | |
| SCHEMBL30417508 | 1.00 | HCRTR2 (1.00) | HCRTR2HCRTR1MEN1KMT2AKDM4E | |
| SCHEMBL12978652 | 1.00 | HCRTR2 (1.00) | HCRTR2HCRTR1MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL15544842 | 0.99 | HCRTR2 (0.98) | HCRTR2HCRTR1MEN1KMT2AKDM4E | |
| SCHEMBL6333557 | 0.90 | HCRTR2 (1.00) | HCRTR2HCRTR1KMT2AKDM4EALDH1A1 | |
| SCHEMBL6328598 | 0.84 | HCRTR2 (0.81) | HCRTR2HCRTR1 | |
| SCHEMBL6978577 | 0.82 | HCRTR2 (0.72) | HCRTR2HCRTR1 | |
| SCHEMBL6327967 | 0.82 | HCRTR2 (1.00) | HCRTR2HCRTR1MEN1KMT2AKDM4E | |
| SCHEMBL6333854 | 0.82 | HCRTR2 (0.71) | HCRTR2HCRTR1KDM4EALDH1A1TSHR | |
| SCHEMBL6331702 | 0.82 | HCRTR2 (0.71) | HCRTR2HCRTR1KDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894042-B2 | Methods and pharmaceutical compositions for the treatment of cancer | Inserm (Institut National de la Santa et de la Recherche Medicale) (FR) | 2021-01-19 | — | — | US | disclosed |
| US-20190151304-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-05-23 | — | — | US | disclosed |
| US-20190083508-A1 | USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-21 | — | — | US | disclosed |
| US-20130217729-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | US | disclosed |
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-20120258957-A1 | HETEROCYCLIC DERIVATIVES | MSD OSS B.V. (NL) | 2012-10-11 | — | — | US | disclosed |
| EP-2504316-A1 | HETEROCYLIC COMPOUNDS AS ANTAGONISTS OF THE OREXIN RECEPTORS | MSD Oss B.V. (NL) | 2012-10-03 | — | — | EP | disclosed |
| US-20120238602-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | KNUST HENNER (DE) | 2012-09-20 | — | — | US | disclosed |
| US-8202888-B2 | Piperidine sulphonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-2303871-B1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090203736-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | US | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-7501541-B2 | Malonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20080249180-A1 | MALONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | US | disclosed |
| US-20050148634-A1 | 1-N-Aminobenzimidazole derivatives | ZERIA PHARMACEUTICAL CO., LTD (JP) | 2005-07-07 | — | — | US | disclosed |
| US-6838465-B2 | N-acyltetrahydroisoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| US-20040044031-A1 | N-acyltetrahydroisoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203736-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | HCRTR2, PER2, HCRTR1 | HCRTR2 1/4885HCRTR1 3/4885MEN1 2182/4885 |
| US-20120238602-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | HCRTR2, PER2, HCRTR1 | HCRTR2 1/4885HCRTR1 3/4885MEN1 2182/4885 |
| US-20040044031-A1 | N-acyltetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, OPRL1 | HCRTR2 1/4885HCRTR1 2/4885MEN1 3009/4885 |
| US-20190151304-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY | HCRTR1, HCRTR2, OXTR | HCRTR2 2/4885HCRTR1 1/4885MEN1 2483/4885 |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | HCRTR2 1/4885HCRTR1 2/4885MEN1 1776/4885 |
| US-20120258957-A1 | HETEROCYCLIC DERIVATIVES | HCRTR2, HCRTR1, NPY5R | HCRTR2 1/4885HCRTR1 2/4885MEN1 754/4885 |
| US-10894042-B2 | Methods and pharmaceutical compositions for the treatment of cancer | OXTR, OGFR, OXGR1 | HCRTR2 14/4885HCRTR1 18/4885MEN1 1980/4885 |
| US-20050148634-A1 | 1-N-Aminobenzimidazole derivatives | CYP1B1, CYP2E1, CYP1A1 | HCRTR2 4425/4885HCRTR1 4010/4885MEN1 4155/4885 |
| US-20090312314-A1 | HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | HCRTR2 1/4885HCRTR1 2/4885MEN1 1019/4885 |
| US-20080249180-A1 | MALONAMIDES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, MTNR1B | HCRTR2 1/4885HCRTR1 2/4885MEN1 453/4885 |
| US-20190083508-A1 | USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | GPR180, OXGR1, MLNR | HCRTR2 17/4885HCRTR1 22/4885MEN1 4617/4885 |
| US-20130217729-A1 | PIPERIDINE SULPHONAMIDE DERIVATIVES | HCRTR2, PER2, HCRTR1 | HCRTR2 1/4885HCRTR1 3/4885MEN1 2182/4885 |
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, MTNR1A | HCRTR2 1/4885HCRTR1 2/4885MEN1 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.